Drugs are one of the representative exogenous agents that cause photosensitive dermatitis. Both phototoxic and photoallergic mechanisms exist in photosensitivity to exogenous agents. While the phototoxic reaction is mediated mainly by reactive oxygen species, the photoallergic reaction is induced and elicited by immunological conse- This review aims to highlight the mechanism of drug photoallergy, focusing on the assessments of photoallergenicity as well as phototoxicity of chemicals. A recent finding that --
immunomodulatory drugs can induce photosensitivity is also mentioned.
| PROPERTIES OF PHOTOSE NSITIZERS

| Two types of photosensitivity to chemicals
Photosensitive materials have two properties, phototoxicity and photoallergenicity. The phototoxic reaction eventually results in a cellular cytotoxicity, while the photoallergic reaction is induced and elicited by immunological consequences involving various immunocompetent cells and molecules. [6] [7] [8] Each photosensitive chemical has different dominancy to phototoxicity or photoallergenicity. For example, psoralen and porphyrin derivatives are strong phototoxic agents with scarce photoallergenicity and thus used for photochemotherapy or photodynamic therapy with few photoallergic adverse effects. 9 By contrast, ketoprofen and fluoroquinolones (FQs) are causative agents for photocontact dermatitis and drug photoallergy, respectively. 7 It is noted, however, that all photoallergic chemicals have a phototoxic property because the photoallergic reaction requires the initial phototoxic step ( Figure 1 ) in which photosensitizers bind to protein via the formation of reactive oxygen species (ROS). 1 Historically, it was believed that most cases of photocontact dermatitis and drug photoallergy are induced by the phototoxic reaction, and the incidence of the photoallergic reaction is low.
However, recent clinical studies have suggested that the photoallergic type is rather common. 7 This misunderstanding seems to be caused by easy evaluation of phototoxicity and difficult assessment of photoallergenicity.
The action spectrum (the provocative light wavelength) of these two types of photosensitivity is mostly ultraviolet A light (UVA; 320-400 nm). 1 Ultraviolet B light (UVB; 290-320 nm) rarely evokes the diseases, as represented by photosensitivity to drugs, such as sulfanilamide, 10 ranitidine, 11 and bicalutamide. 12 Photoaugmentation by UVA and UVB is occasionally seen in some drugs. 13 
| Phototoxicity
Phototoxicity is mainly caused by generation of ROS. 13, 14 Singlet oxygen is most important for chemical phototoxicity and the generally termed type II photodynamic reaction. 14 The target molecules of phototoxic chemicals include proteins or amino acids, lipids, and DNA, 13, 14 and their alterations lead to cellular damage or even cellular death ( Figure 1 ). Therefore, cellular cytotoxicity has been used as a classical method to evaluate phototoxicity. Both necrosis and apoptosis occur in cells phototreated with chemicals and UV. 15 Various cells have been utilized for cytotoxicity assessments, including erythrocytes, fibroblasts, keratinocytes, macrophages, lymphocytes, and even fungi, but the reduction in neutral red uptake (NRU) in phototreated fibroblasts (3T3) has been the standard assessment.
16
Phototoxicity can also be evaluated using target molecules, and such tests include protein (histidine, lysine, and cysteine) degradation, lipid oxidation, and plasmid DNA-breaking activity. 13 In addition, the binding capacity of chemicals to protein upon exposure to UV is a phototoxicity test. 17 determinant. Thus, it is now thought that photobinding of agents with protein represents a photoallergic potency of a given chemical (Figure 1 ).
| Photoallergenicity
Photoallergy is a well-organized immunological reaction. The pathogenesis of contact dermatitis and drug hypersensitivity is based on the hapten hypothesis 18 : A hapten binds covalently to protein, and the resulting conjugate can be recognized as immunogenic determinants. Likewise, photosensitive materials have a haptenic moiety.
Two hypotheses have been put forward to explain the formation of photoallergens (Figure 2 and exhibits an eczematous eruption consisting of erythema, papules/vesicles, and occasionally bullae, at the skin sites where a photocontactant is applied. 21 The action spectrum of this photosensitivity is mainly UVA. The sensitivity is divided into two, phototoxic and photoallergic, types. 21 Recent attention to phototoxic materials has decreased the incidence of the phototoxic type of photocontact dermatitis. Therefore, the incidence of photoallergy is now thought to be higher than that of phototoxicity. Drug photosensitivity is one of the adverse reactions of systemically administered drugs 35 and is clinically recognized as skin eruptions on sun-exposed areas, including cheeks, nose, forehead, posterior nuchal area, V area of neck, dorsal aspect of hands, extensor surface of forearms, and lower legs. The action spectrum is usually UVA, although UVB may exceptionally induce the sensitivity or augment the level of UVA-induced sensitivity. 13 It should be noted that the absorption spectrum and the action spectrum are same in phototoxicity; however, the action spectrum is shifted from the absorption spectrum to longer wave range in photoallergy.
Drug photosensitivity usually shows erythematous eruption and lichenoid eruption, and occasionally bullous eruption and leukomelanoderma. The erythematous eruption is the common type of drug photoallergy and may have scaling on the surface. The lichenoid eruption is occasionally similar to lichen planus. 36 This type is clinically characterized by erythematous but dark-colored papules and histologically by CD8 + T-cell infiltration in the upper dermis and attacking keratinocytes. 37 Leukomelanoderma displays a unique clinical appearance of a mixture of pigmentation and depigmentation and occurs in dark-colored individuals such as Japanese. In some patients with the erythematous, lichenoid, and bullous eruptions, biopsied specimens exhibit infiltration of eosinophils as well as lymphocytes. 38 Various drugs have been reported to induce photosensitivity, including quinolones as represented by fluoroquinolones (FQs), 7, 39, 40 afloqualone (AQ), 17, 41 NSAIDs, 24, 26, 42, 43 Again, there are phototoxic 13, 26 and photoallergic 7, 17, 19, 37, 39, 40 mechanisms in drug photosensitivity. 7 However, discrimination of these two mechanisms is not necessarily easy. For example, sparfloxacin shows apparent phototoxicity, 13 as positive phototest was shown in virtually all subjects taking sparfloxacin. However, long-term administration of sparfloxacin and exposure to sunlight evoked lichenoid tissue reaction, an immunological change. 37 It is probably difficult to discriminate photoallergy and phototoxicity, and both are mixed to various extents in clinical settings. In photoallergic drug eruption, the vast majority of photosensitizing drugs are photohapten rather than prohapten. The main sequential events in allergic photocontact dermatitis and drug photosensitivity are virtually the same as those of ordinary contact dermatitis and drug eruption, except for the requirement of UV irradiation in sensitization and challenge. Photobinding of chemicals to skin constituents is the initial step of drug photoallergy (Figure 3) . In photocontact dermatitis, a chemical is applied to the skin from the outside.
Meanwhile, in drug photosensitivity, a systemically administered drug diffuses to the epidermis from the blood. Protein is covalently bound to a photodegradated site of photohapten to form an allergic photohapten-protein complex. 7 Lysine is a preferential amino acid to allow binding to FQs, 40 but other amino acids possibly afford the binding sites.
UVA is the action spectrum of photoderivatization of protein with photosensitizers. 17 This is in accordance with the historical notion that in the case of photoallergic reaction to exogenous agents, the action spectrum is shifted from its absorption wavelength to a longer wavelength. Thus, even if the absorption spectrum of a given material is UVB, its action spectrum falls in UVA wave range.
| Photomodification of epidermal keratinocytes with drugs
Upon photobinding of photosensitizers to protein, epidermal cells In addition, uptake of drugs by keratinocytes and irradiation with UVA would produce ROS, leading to activation of antioxidant response element.
| Photomodification of DCs with drugs
In parallel with photoconjugation of keratinocytes, DCs, including There have been various in vitro phototoxicity tests. Cytotoxic assays are common and evaluated using fibroblasts (3T3), erythrocytes, Candida albicans, macrophages, lymphocytes, and keratinocytes.
3T3 NRU phototoxicity test was adopted by OECD guideline in 2004.
ROS assay was adopted in the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) S10 guideline (2013). Plasmid DNA-breaking activity was proposed as a sensitive method. 57 The phototoxicity of chemicals also can be assessed by their activities to bind to protein and amino acids, and resultant reduction in certain amino acids. It is notable that the ability to bind to proteins/amino acids also indicates photoallergenicity of chemicals.
| Photoallergenicity assessments
As for photoallergy, several in vitro methods have been proposed, but none of them has yet been accepted for prediction tests (Table 1 ). In vitro assessments of photoallergic potentials of chemicals reflect one or two steps of the sensitivity. The major In photo-DPRA, cysteine, lysine, and histidine are representative candidates to afford binding sites to sensitizers under UV irradiation.
Reduction in these amino acids after treatment of proteins with chemical and UVA suggests its photoallergenicity.
Antioxidant response element (ARE) assay is used to test sensitizers or photosensitizers, and it targets guideline. Uptake of a chemical by keratinocytes and irradiation with UVA would produce ROS, leading to activation of ARE. Therefore, photosensitizer plus UVA activates Keap1-Nrf2-ARE pathway in keratinocytes ( Figure 4 ). TCSA shows the pattern of photohapten. 59 As haptenic materials, it may be reasonable that the estimated concentration that yields a stimulation index of two (EC2) is appropriate for CD54 expression and EC1.5 is for CD86. 59 When the phototreated cells express higher levels of MHC class II and costimulatory molecules, such as CD86, CD80 or CD40, the substance would have an ability to photosensitize and photoelicit T cells. antibody, targeting CCR4, and was first approved in Japan for the treatment of adult T-cell leukemia/lymphoma (ATLL), followed by cutaneous T-cell lymphoma and peripheral T-cell lymphoma. We Attention should be paid to new types of photosensitivity, which are represented by the immune-related adverse effect of mogamulizumab. 61 Our recent observation on voriconazole photocarcinogenesis further suggests that a prodrug and its metabolite play different roles in conjunction with UV and construct a photodisordered condition. 62 Finally, recently marketed drugs, such as pirfenidone, 63 show that a long-term phototoxic reaction possibly leads to a photoallergic response.
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